Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06907420 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

40 Hz Visual Stimulation as an Intervention in Schizophrenia

Study acronym: GammaSZ
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 2, 2025 (before its estimated June 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Minor Study First Submitted
In schizophrenia, an abnormal reduction in neuronal gamma oscillations (30-100 Hz) is associated with negative symptoms such as cognitive dysfunction. The literature suggests that rescuing gamma oscillations through non-invasive brain stimulation may be an accessible and safe add-on strategy to mitigate negative symptoms. Here, a stimulation protocol based on gamma visual stimulation will be tested. This pilot study will follow an uncontrolled clinical trial design: A minimum of ten patients diagnosed with schizophrenia or a schizoaffective disorder and predominant negative symptoms will be recruited at Klinikum rechts der Isar. They will undergo a multisession stimulation protocol, consisting of one hour of 40 Hz visual stimulation per day over five consecutive days, during which they will be encouraged to fall asleep. An equal number of patients will be recruited for a treatment-as-usual group without intervention. Pre- and post-assessments will include EEG, a cognitive test battery (THINC-IT), a mood scale (PANAS), and a schizophrenia symptom scale (PANSS). This study's results will inform on the feasibility of gamma visual stimulation as a potential add-on intervention in schizophrenia.
Trial Details
NCT Number NCT06907420
Lead Sponsor Technical University of Munich
Conditions
(from sponsor)
Negative Symptoms in Schizophrenia, Schizophrenia Disorders, Schizoaffective Disorder
Related terms photopsia, Psychotic Disorders, Schizophrenia
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov